{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:05:04Z","timestamp":1789758304218,"version":"4.0.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Recent clinical trials demonstrated that proprotein convertase subtilisin\/kexin 9 (PCSK9) inhibitors reduce cardiovascular events without affecting systemic inflammation in the patients with coronary artery disease, as determined by high sensitivity C-reactive protein (CRP) levels. However, its pro-inflammatory effects in cardiovascular disease in humans and experimental animals beyond the traditional cholesterol receptor-dependent lipid metabolism have also called attention of the scientific community. PCSK9 may target receptors associated with inflammation other than the low-density lipoprotein <jats:sans-serif>receptor (<\/jats:sans-serif>LDLR) and members of the LDLR family. Accumulating evidence suggests that PCSK9 promotes macrophage activation not only via lipid-dependent mechanisms, but also lipid-independent and LDLR-dependent or -independent mechanisms. In addition to dyslipidemia, PCSK9 may thus be a potential therapeutic target for various pro-inflammatory diseases.<\/jats:p>","DOI":"10.3389\/fcvm.2024.1431398","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T04:39:11Z","timestamp":1722487151000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["The role of proprotein convertase subtilisin\/kexin 9 (PCSK9) in macrophage activation: a focus on its LDL receptor-independent mechanisms"],"prefix":"10.3389","volume":"11","author":[{"given":"Shunsuke","family":"Katsuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhash Kumar","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/MOL.0000000000000919","article-title":"PCSK9-directed therapies: an update","volume":"35","author":"Katzmann","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41467-017-00568-7","article-title":"Heparan sulfate proteoglycans present PCSK9 to the LDL receptor","volume":"8","author":"Gustafsen","year":"2017","journal-title":"Nat Commun"},{"key":"B4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.cmet.2014.01.013","article-title":"Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes","volume":"19","author":"Lee","year":"2014","journal-title":"Cell Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/eurheartj\/ehz566","article-title":"Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin\/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin\/kexin type-9","volume":"41","author":"Jang","year":"2020","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/ars.2016.6631","article-title":"Cross-talk between PCSK9 and damaged mtDNA in vascular smooth muscle cells: role in apoptosis","volume":"25","author":"Ding","year":"2016","journal-title":"Antioxid Redox Sign"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/cvr\/cvab034","article-title":"Dynamin-related protein 1 inhibition reduces hepatic PCSK9 secretion","volume":"117","author":"Rogers","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1016\/j.celrep.2015.11.006","article-title":"GRP94 regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation","volume":"13","author":"Poirier","year":"2015","journal-title":"Cell Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"Raber","year":"2022","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"L53","DOI":"10.1093\/eurheartj\/suaa135","article-title":"Lipoprotein(a) and PCSK9 inhibition: clinical evidence","volume":"22","author":"Ruscica","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3389\/fgene.2020.01020","article-title":"PCSK9 variants in familial hypercholesterolemia: a comprehensive synopsis","volume":"11","author":"Guo","year":"2020","journal-title":"Front Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100366","DOI":"10.1016\/j.ajpc.2022.100366","article-title":"Intensive lipid lowering agents and coronary atherosclerosis: insights from intravascular imaging","volume":"11","author":"Di Giovanni","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the FOURIER trial","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","article-title":"PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia","volume":"38","author":"Bernelot Moens","year":"2017","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"117180","DOI":"10.1016\/j.atherosclerosis.2023.06.971","article-title":"Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque","volume":"378","author":"Marfella","year":"2023","journal-title":"Atherosclerosis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation","volume":"288","author":"Kosenko","year":"2013","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","article-title":"Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels","volume":"220","author":"Ferri","year":"2012","journal-title":"Atherosclerosis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/CIRCRESAHA.121.320056","article-title":"Proprotein convertase subtilisin\/kexin 9 (PCSK9) promotes macrophage activation via LDL receptor-independent mechanisms","volume":"131","author":"Katsuki","year":"2022","journal-title":"Circ Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1194\/jlr.M051326","article-title":"Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin","volume":"55","author":"K\u00fchnast","year":"2014","journal-title":"J Lipid Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues","volume":"107","author":"Ding","year":"2015","journal-title":"Cardiovasc Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/cvr\/cvy079","article-title":"PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/path.4630","article-title":"Local effects of human PCSK9 on the atherosclerotic lesion","volume":"238","author":"Giunzioni","year":"2016","journal-title":"J Pathol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/cvr\/cvw053","article-title":"Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms","volume":"110","author":"Tavori","year":"2016","journal-title":"Cardiovasc Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation"},{"key":"B34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"20963","DOI":"10.1074\/jbc.272.34.20963","article-title":"Low density lipoprotein oxidation and its pathobiological significance","volume":"272","author":"Steinberg","year":"1997","journal-title":"J Biol Chem"},{"key":"B36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/glycob\/cwh038","article-title":"A syndecan-4\/CXCR4 complex expressed on human primary lymphocytes and macrophages and HeLa cell line binds the CXC chemokine stromal cell-derived factor-1 (SDF-1)","volume":"14","author":"Hamon","year":"2004","journal-title":"Glycobiology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1165\/rcmb.2011-0294OC","article-title":"Syndecan-4 regulates early neutrophil igration and pulmonary inflammation in response to lipopolysaccharide","volume":"47","author":"Tanino","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/mt.2011.260","article-title":"PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates","volume":"20","author":"Lindholm","year":"2012","journal-title":"Mol Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0191895","DOI":"10.1371\/journal.pone.0191895","article-title":"Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice","volume":"13","author":"Kawakami","year":"2018","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.2174\/0929867329666220930114429","article-title":"The immunogenic potential of PCSK9 peptide vaccine in mice","volume":"30","author":"Ataei","year":"2023","journal-title":"Curr Med Chem"},{"key":"B42","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"E177","DOI":"10.1152\/ajpendo.00528.2014","article-title":"New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism","volume":"309","author":"Miyosawa","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1161\/CIRCRESAHA.114.302937","article-title":"Induction of atherosclerosis in mice and hamsters without germline genetic engineering","volume":"114","author":"Bjorklund","year":"2014","journal-title":"Circ Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1161\/ATVBAHA.114.303617","article-title":"Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9","volume":"35","author":"Roche-Molina","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.atherosclerosis.2011.08.035","article-title":"The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography","volume":"219","author":"Awan","year":"2011","journal-title":"Atherosclerosis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/dom.14547","article-title":"Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: the CAVEAT study","volume":"24","author":"Marfella","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B48","doi-asserted-by":"publisher","first-page":"166ra1","DOI":"10.1126\/scitranslmed.3004853","article-title":"Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant","volume":"5","author":"Al-Mashhadi","year":"2013","journal-title":"Sci Transl Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2016.06.011","article-title":"A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification","volume":"251","author":"Goettsch","year":"2016","journal-title":"Atherosclerosis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1172\/JCI80851","article-title":"Sortilin mediates vascular calcification via its recruitment into extracellular vesicles","volume":"126","author":"Goettsch","year":"2016","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/CIRCRESAHA.116.310293","article-title":"Dynamin-related protein 1 inhibition attenuates cardiovascular calcification in the presence of oxidative stress","volume":"121","author":"Rogers","year":"2017","journal-title":"Circ Res"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1431398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T04:39:13Z","timestamp":1722487153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1431398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":51,"alternative-id":["10.3389\/fcvm.2024.1431398"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1431398","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"article-number":"1431398"}}